GCVI Summit 2018
Skip Content

14 November 2017

Arcus arms itself with $107m

Immunotherapy developer Arcus Biosciences has raised series C funding from a GV-led consortium that included Celgene and Taiho.

Author: Thierry Heles, Reporter

US-based cancer-focused biotechnology producer Arcus Biosciences raised $107m in series D capital yesterday from investors led by GV, the early-stage investment arm of internet and technology conglomerate Alphabet.